02325nam a22005051i 4500 000711078 CaToSAGE 20240202172917.0 20170113114348.0 m|||||o||d|||||||| cr ||||||||||| 170109r20172014enk fo 000 0 eng d NEZPRACOVANÝ IMPORT 9781526403124 (ebook) : No price (OCoLC)1017732847 CaToSAGE eng CaToSAGE rda pn UtOrBLW HF5387 .B83 2017 174.4 Budish, Benjamin, author. Gilead Sciences and Sovaldi : the cost of a cure (B) / Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke. London : SAGE Publications Ltd, 2017. 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier SAGE Knowledge. Cases Originally published in Budish, B., Lane, C., Zaleski, R., & ORourke, J. S. (2014). Gilead Sciences and Sovaldi: The cost of a cure (B). 14-10 (B). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame. Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S. Description based on XML content. elektronické knihy fd186907 czenas electronic books eczenas Gilead Sciences (Firm) Business ethics. Strategic planning. Pharmaceutical industry. Lane, Chase, author. Zaleski, Richard, author. O'Rourke, James S., 1946- author. SAGE Knowledge. Cases. SAGE Knowledge https://sk.sagepub.com/cases/gilead-sciences-and-sovaldi-the-cost-of-a-cure-b Plný text SBC EB NEPOSILAT EB